Threshold cumulative Development milestone achievement for receiving contingent consideration under asset acquisition.

No definition available.

Name:	amph_AssetAcquisitionContingentConsiderationThresholdCumulativeDevelopmentMilestone
Namespace Prefix:	amph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Threshold cumulative sales milestone achievement for receiving contingent consideration under asset acquisition.

+ References

No definition available.

+ Details

Name:	amph_AssetAcquisitionContingentConsiderationThresholdCumulativeSalesMilestone
Namespace Prefix:	amph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Maximum Royalty Amount Owed, Contingent On Sales of Products

+ References

No definition available.

+ Details

Name:	amph_MaximumRoyaltyAmountOwedContingentOnSalesOfProducts
Namespace Prefix:	amph_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents number of licensed products.

+ References

No definition available.

+ Details

Name:	amph_NumberOfLicensedProducts
Namespace Prefix:	amph_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Royalty Payment Percentage

+ References

No definition available.

+ Details

Name:	amph_RoyaltyPaymentPercentage
Namespace Prefix:	amph_
Data Type:	dtr-types:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The cash outflow for purchases of and capital improvements on property, plant and equipment (capital expenditures), software, and other intangible assets.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480060/805-50-25-1

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-1

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 50
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480027/805-50-30-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Subparagraph (c)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-13

+ Details

Name:	us-gaap_PaymentsToAcquireProductiveAssets
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_TypeOfArrangementAxis=amph_LicensingAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RelatedPartyTransactionsByRelatedPartyAxis=amph_NanjingHanxinPharmaceuticalTechnologyCoLtdMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=amph_NanjingAnjiBiotechnologyCo.Ltd.Member
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amph_DevelopmentMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=amph_SalesMilestonePaymentsMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_ProductOrServiceAxis=us-gaap_RoyaltyMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments and Contingencies (Licensing Agreement) (Details) - Licensing Agreement	1 Months Ended		3 Months Ended	12 Months Ended
	Jan. 31, 2026 USD ($)	Aug. 31, 2025 USD ($)	Mar. 31, 2026 USD ($)	Dec. 31, 2025 USD ($)
Hanxin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Cash payment			$ 2,000,000
Royalty Payment Percentage	5.00%
Hanxin \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum royalty amount owed, contingent on sales of products	$ 60,000,000
Nanjing Anji Biotechnology Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of licensed products		3
Cash payment				$ 6,000,000
Royalty Payment Percentage		5.00%
Nanjing Anji Biotechnology Co., Ltd. \| Maximum
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum royalty amount owed, contingent on sales of products		$ 60,000,000
Development Milestone Payments \| Hanxin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold Cumulative Development Milestones	14,000,000
Development Milestone Payments \| Nanjing Anji Biotechnology Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold Cumulative Development Milestones		42,000,000
Sales Milestone Payments \| Hanxin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold cumulative sales milestone	75,000,000
Sales Milestone Payments \| Nanjing Anji Biotechnology Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Threshold cumulative sales milestone		225,000,000
Royalty Payments \| Hanxin
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum royalty amount owed, contingent on sales of products	$ 7,500,000
Royalty Payments \| Nanjing Anji Biotechnology Co., Ltd.
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Maximum royalty amount owed, contingent on sales of products		$ 22,500,000